Key result
LGALS13 -98A/A genotype combined with maternal risk factors predicts ~16-fold higher term preeclampsia risk.
Why the study?
LGALS13 promoter DNA polymorphisms and maternal risk factors have potential to predict preeclampsia in the first trimester but require evaluation.
Does the combination of LGALS13 -98A/A genotype and maternal risk factors predict the development of preeclampsia in the first trimester?
Case-Control (n=263)
No
Does the combination of LGALS13 -98A/A genotype and maternal risk factors predict the development of preeclampsia in the first trimester?
The combination of the LGALS13 -98A/A genotype with maternal risk factors significantly improves the prediction of preeclampsia in the first trimester.
BACKGROUND: LGALS13 (placental protein 13 [PP13]) promoter DNA polymorphisms was evaluated in predicting preeclampsia (PE), given PP13's effects on hypotension, angiogenesis, and immune tolerance. METHODS: First-trimester plasma samples (49 term and 18 intermediate) of PE cases matched with 196 controls were collected from King's College Hospital, London, repository. Cell-free DNA was extracted and the LGALS13 exons were sequenced after PCR amplification. Expression of LGALS13 promoter reporter constructs was determined in BeWo trophoblast-like cells with luciferase assays. Adjusted odds ratio (OR) was calculated for the A/A genotype combined with maternal risk factors. RESULTS: The A/A, A/C, and C/C genotypes in the -98 promoter position were in Hardy-Weinberg equilibrium in the control but not in the PE group (p < 0.036). The dominant A/A genotype had higher frequency in the PE group (p < 0.001). The A/C and C/C genotypes protected from PE (p < 0.032). The ORs to develop term and all PE, calculated for the A/A genotype, previous PE, body mass index (BMI) >35, black ethnicity, and maternal age >40 were 15.6 and 11.0, respectively (p < 0.001). In luciferase assays, the "-98A" promoter variant had lower expression than the "-98C" variant in non-differentiated (-13%, p = 0.04) and differentiated (-26%, p < 0.001) BeWo cells. Forskolin-induced differentiation led to a larger expression increase in the "-98C" variant than in the "-98A" variant (4.55-fold vs. 3.85-fold, p < 0.001). CONCLUSION: Lower LGALS13 (PP13) expression with the "A" nucleotide in the -98 promoter region position (compared to "C") and high OR calculated for the A/A genotype in the -98A/C promoter region position, history of previous PE, BMI >35, advanced maternal age >40, and black ethnicity could serve to aid in PE prediction in the first trimester.
No takes yet. Share an insight, caveat, or question.
Madar-Shapiro et al. (2017) conducted a case-control in Preeclampsia (n=263). LGALS13 -98A/A genotype combined with maternal risk factors vs. Absence of these combined risk factors was evaluated on Development of term preeclampsia (OR 15.6, p=<0.001). The combination of the LGALS13 -98A/A promoter genotype, previous preeclampsia, BMI >35, black ethnicity, and maternal age >40 strongly predicted the development of term preeclampsia (OR 15.6).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: